Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
G Protein Coupled Receptor (GPCR) expert will invest up to €3M ($3.3M) to unlock the therapeutic potential of breakthrough asset
Ermium Therapeutics announced a series A funding of €6.3 M with Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo.
Advanced Medical Solutions Group plc announces its unaudited interim results for the six months ended 30 June 2019.
Amphion Innovations plc announces that 1,150,000 shares in Partner Company, Polarean Imaging plc have been sold for partial repayment of the loan facility originally announced on 5 June 2014 and most recently amended as announced on 1 April 2019.
InDevR, Inc. announced that it has raised a $7 million Series A round of equity financing from Adjuvant Capital.
Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.
Proceeds to fund multi-centre study of STAR Mapping to improve outcomes of persistent Atrial Fibrillation treatment
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
Lightcast Discovery Ltd announces that it has raised £1.3 m in seed financing from private investors to develop the capabilities and applications of its platform including continuing to expand its range of pilot studies.
4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close